The NCI has recognized that the achievement of 21st century molecular-based medicine, including the objective of eliminating suffering and death due to cancer, requires a commitment to a new kind of scientific enterprise. Such an enterprise is characterized by “team science” across multiple laboratories that share data in standardized formats; collaborations among academic, private, and public sector organizations; and high-throughput technology platforms supported by seamless informatics capability and systems-level planning and management. NCI has thus developed and launched several technology initiatives, which in the aggregate are intended to transform the landscape of cancer research, and ultimately, the lives of cancer patients.
- Advanced Technology Initiatives– Read about OTIR’s Advanced Technology Initiatives in the areas of nanotechnology, proteomics, molecular analysis, and biosensors, which work to accelerate the pace of cancer research and the translation of research results into new therapies, diagnostics, and preventive agents.
- SBIR & STTR Program – Learn about the NCI SBIR & STTR Program, which fosters research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many other areas of interest to the NCI.
- Partnerships – View the partnerships the NCI has established with the Food and Drug Administration (FDA), the National Institute of Standards and Technology (NIST), the National Science Foundation (NSF), and other government agencies.
- NCI Related Initiatives – Find out how OTIR is collaborating with related NCI initiatives, including the cancer Biomedical Informatics Grid (caBIG™), the Office of Biorepositories and Biospecimen Research (OBBR), and the Office of Cancer Genomics (OCG).